Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyAetna Antiprothrombin Antibody Testing Coverage | …
    Ask Trek AI about this page
    CurrentAetnaPolicy 0662

    Antiprothrombin Antibody Testing

    Customize your policy alerts

    Sign up for Aetna Policy 0662 alerts

    Get alerted when Policy 0662 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of antiprothrombin antibody testing (laboratory tests for antibodies to prothrombin and related phosphatidylserine/prothrombin complex) for Aetna members; it states Aetna's coverage stance and provides supporting background and references for clinicians and reviewers.

    Policy Summary
    PayerAetna
    PolicyAntiprothrombin Antibody Testing
    Policy CodePolicy 0662
    Change TypeNo material change
    Effective DateMay 2, 2003
    Last ReviewSep 14, 2023
    Next Review DateJul 11, 2024
    Key ActionDo not submit claims for antiprothrombin antibody testing expecting coverage because Aetna considers these tests experimental and investigational.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    experimental
    coverage determination
    0662policy number
    23references
    09/14/2023last review
    07/11/2024next review

    Coverage Determination

    inv-01: Not covered — experimental and investigational

    Covered when ALL of the following are met:

    Experimental/Investigational Determination: Aetna considers antiprothrombin antibody testing experimental and investigational because its clinical value has not been established.

    Policy statement

    Aetna considers antiprothrombin antibody testing experimental and investigational because its clinical value has not been established. Accordingly, antiprothrombin antibody testing is not eligible for coverage or reimbursement under this policy.

    Studies of phosphatidylserine-dependent antiprothrombin antibodies (aPS/PT) report mixed findings regarding clinical utility. For example, Sugiura-Ogasawara et al. (2004) concluded that aPS/PT antibodies are not useful markers for high-risk women with recurrent miscarriages, while other reports have explored associations with pregnancy loss and potential diagnostic value but without consensus across studies.

    Because the clinical significance and reproducibility of antiprothrombin antibody assays remain unestablished, testing for antiprothrombin antibodies is deemed investigational and is not considered medically necessary for diagnosis, risk stratification, or management decisions.

    Clinical Contexts Studied

    inv-20: Clinical contexts where antiprothrombin or aPS/PT antibodies have been studied (APS, thrombosis, pregnancy loss), background on study settings

    Clinical contexts in which antiprothrombin or phosphatidylserine-dependent antiprothrombin (aPS/PT) antibodies have been studied include the following:

    ONE of: Evaluation of patients with suspected antiphospholipid syndrome (APS), as antiprothrombin antibodies have been described in patients with APS but their clinical significance is not well defined.

    Background: APS features and antibody testing

    ONE of: Assessment of thrombotic events (venous or arterial thromboses) in which antiprothrombin antibodies have been investigated as potential markers but with uncertain specificity for thrombosis.

    British Committee for Standards in Haematology commentary on specificity

    ONE of: Investigation of pregnancy morbidity, including recurrent pregnancy loss and early pregnancy loss, where some studies (e.g., von Landenberg et al. 2003) reported associations but guidelines (ACOG 2005) have not recommended routine clinical use.

    Relevant Codes

    Related CPT / HCPCS CodesCPT
    85300-85306Clotting inhibitors or anticoagulants; antithrombin III, activity, antithrombin III, antigen assay, protein C, antigen, protein C, activity, protein S, total, or protein S, free.
    86147Cardiolipin (phospholipid) antibody, each Ig class.
    86148Anti-phosphatidylserine (phospholipid) antibody.
    86880Antihuman globulin test (Coombs test); direct, each antiserum.
    ICD-10 Codes (examples listed in policy)ICD-10
    D68.61Antiphospholipid syndrome.
    N96Recurrent pregnancy loss.
    O26.20-O26.23Pregnancy care for patient with recurrent pregnancy loss.

    Provider Responsibilities & Billing Notes

    Billing Rule

    Coding References for Test Claims

    Providers should report tests using the CPT/HCPCS codes listed for antiphospholipid and related antibody testing. When submitting claims, include the most specific code available and any required modifiers or diagnosis pointers.

    • Report the most specific CPT/HCPCS code from the list when performing antiphospholipid/antiprothrombin-related testing.
    • Include relevant ICD-10 diagnosis codes (e.g., D68.61, N96, O26.20–O26.23) to support medical necessity where applicable.
    Denial Risk

    Denial Risk for Experimental Testing

    Aetna considers antiprothrombin antibody testing experimental and investigational because its clinical value has not been established. Claims for testing deemed experimental/investigational may be denied.

    Who May Order & Ordering Notes

    Note

    Ordering authority not specified in policy excerpts

    The policy excerpts do not define who may order antiprothrombin antibody testing; the document focuses on testing modality and evidence rather than ordering-provider restrictions.

    Note

    No provider-type ordering restrictions stated

    No specific ordering-provider restrictions are listed in the provided excerpts.

    Tests Not Covered

    Antiprothrombin antibody testing — including assays for antibodies to prothrombin and the phosphatidylserine–prothrombin (PS/PT) complex — is considered not covered because it is classified as experimental and investigational due to unproven clinical value.

    Testing for phosphatidylserine-dependent antiprothrombin antibodies may have limited utility in some research contexts or select clinical investigations, but published work (e.g., Sugiura-Ogasawara et al., 2004) found these antibodies were not useful markers for identifying high-risk women with recurrent miscarriage.

    Testing Frequency Guidance

    Frequency limits
    Policy frequency recommendationNo specific frequency limits are specified in the policy; routine performance of antiprothrombin/aPS‑PT testing is not recommended because of reproducibility and interpretation concerns.
    Reason for limiting routine useInter-laboratory and inter-assay discordance and problems with reproducibility and interpretation were reported across multiple methods (homemade and commercial).
    Implication for clinical useTesting should not be performed routinely for surveillance; results require cautious interpretation and correlation with clinical context and other aPL tests.
    Additional frequency-related notes
    Inter-assay variability noteComparative studies found discordant IgM results between assays and only moderate concordance for some IgG methods, indicating variability between methods.
    Test performance in subgroups

    Background and Rationale

    Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by circulating antiphospholipid antibodies and clinical manifestations such as venous or arterial thromboses, thrombocytopenia, and pregnancy morbidity. Most patients with APS have lupus anticoagulant and anticardiolipin antibodies; other antibodies, including antiprothrombin and phosphatidylserine/prothrombin complex antibodies (aPS/PT), have been described but their clinical significance, reproducibility, and role in routine diagnostic criteria remain uncertain. For these reasons, antiprothrombin antibody testing is not supported as a standard diagnostic test for APS.

    Key Terms

    Antiphospholipid syndrome (APS)
    DefinitionAntiphospholipid syndrome (APS) is an autoimmune condition characterized by moderate-to-high levels of circulating antiphospholipid antibodies and clinical features including venous/arterial thromboses, autoimmune thrombocytopenia, fetal loss, transient ischemic attacks and other manifestations.
    Typical antibody profileMost patients with APS have lupus anticoagulant (LA) and anticardiolipin antibodies; testing for both is recommended to confirm diagnosis.
    Clinical manifestationsAPS manifestations include venous and arterial thromboses, recurrent fetal loss, and other features such as livedo reticularis and Coombs‑positive hemolytic anemia.
    Lupus anticoagulant (LA)
    DefinitionLupus anticoagulant (LA) is a laboratory phenomenon detected by its inhibitory actions on coagulation rather than by a direct antigen assay.
    Association with APS
    Policy Summary
    PayerAetna
    PolicyAntiprothrombin Antibody Testing
    Policy CodePolicy 0662
    Change TypeNo material change
    Effective DateMay 2, 2003
    Last ReviewSep 14, 2023
    Next Review DateJul 11, 2024
    Key ActionDo not submit claims for antiprothrombin antibody testing expecting coverage because Aetna considers these tests experimental and investigational.
    SourceLink
    On This Page
    Coverage DeterminationClinical Contexts StudiedRelevant CodesProvider Responsibilities & Billing NotesWho May Order & Ordering NotesTests Not CoveredTesting Frequency GuidanceBackground and RationaleKey Terms

    Mixed study findings and guideline recommendation

    ONE of: Research and method-comparison settings evaluating different assay methods (homemade and commercial aPT and aPS/PT assays) where inter-assay reproducibility and interpretation have been problematic.

    FIRMA collaborative study on assay variability

    inv-21: Evaluation for antiphospholipid syndrome, thrombotic risk assessment, and investigation of recurrent pregnancy loss as addressed in cited literature and guidelines.

    Literature and guideline-based considerations relevant to evaluation for antiphospholipid syndrome (APS), thrombotic risk assessment, and recurrent pregnancy loss:

    Guideline and evidence summary: Current guidelines and task force statements indicate that the clinical significance of anti-prothrombin antibodies has not been defined and testing cannot be recommended for routine clinical use.

    References: British Committee for Standards in Haematology; ACOG (2005); listed references

    Assay performance and reproducibility: Comparative studies (FIRMA collaborative study, Tincani et al. 2007) demonstrated inter-method variability and limited reproducibility across homemade and commercial assays, particularly for IgM results, limiting routine clinical application.

    Inter-laboratory discordance and reproducibility concerns

    Predictive value for obstetric outcomes: Some individual studies (e.g., von Landenberg et al. 2003) found associations between IgG anti-prothrombin antibodies and pregnancy loss, but other studies (e.g., Sugiura-Ogasawara et al. 2004) reported that phosphatidylserine-dependent antiprothrombin antibodies were not useful markers for identifying high-risk women with recurrent miscarriage; overall evidence is inconsistent.

    Conflicting obstetric study results

    Clinical implication for testing: Because of uncertain clinical utility, inconsistent predictive value, and assay variability, antiprothrombin and aPS/PT antibody testing are considered investigational and are not established components of APS diagnostic criteria or routine thrombotic risk stratification.

    Policy conclusion and references

    • Testing for antiprothrombin antibodies is classified as experimental/investigational under this policy.
    • Expect reimbursement denials when services are billed for antiprothrombin antibody testing without coverage justification.
    Documentation Required

    Provider Responsibility & Coverage Enforcement Note

    Clinical Policy Bulletins assist in administering plan benefits and do not constitute medical advice or a description of complete plan benefits. Treating providers are responsible for medical advice and treatment decisions.

    • Use the CPB as a reference for coverage policy; verify member plan specifics and prior authorization requirements separately.
    • Document clinical rationale and relevant diagnoses when submitting claims for review.
    In one comparative study, a commercial IgG/IgM kit (method 5) performed better in patients with thrombosis and pregnancy loss than other methods tested.
    Research vs routine useAlthough some assays (aPS/PT) show promise, the policy cites that further study is needed before establishing frequency or routine testing recommendations.
    LA is commonly present in patients with antiphospholipid syndrome and often coexists with anticardiolipin antibodies.
    Detection approachBecause there is no direct LA assay, detection is based on coagulation assays demonstrating inhibitory activity rather than immunoassays.
    aPS/PT (phosphatidylserine‑dependent antiprothrombin antibodies)
    DefinitionaPS/PT refers to antibodies reactive with the phosphatidylserine–prothrombin (PS/PT) complex (phosphatidylserine‑dependent antiprothrombin antibodies).
    Investigational statusaPS/PT antibodies are under investigation as potential serological markers for APS and may have diagnostic value similar to anticardiolipin in some studies, but are not yet established as routine classification criteria.
    Evidence summarySeveral multicenter and single‑center studies reported that IgG aPS/PT is associated with APS and obstetric complications, but further studies are needed to define clinical utility and standardize assays.
    Antiprothrombin antibodies — assays and diagnostic evaluation
    Assay varietyAntiprothrombin antibodies have been measured using diverse methods, including homemade direct aPT assays, phosphatidylserine‑dependent aPT (aPS/PT) assays, and several commercial kits; performance varies by method.
    Clinical associationsSome studies report associations between antiprothrombin/aPS/PT antibodies and APS manifestations (venous thrombosis, obstetric complications), while other studies find poor specificity for thrombosis or recurrent miscarriage.
    Recommendation on diagnostic evaluationBecause of inter‑assay variability and uncertain clinical significance, antiprothrombin antibody assays are considered investigational and not recommended for routine diagnostic use; results should be interpreted alongside established aPL tests (aCL, anti‑β2‑GPI, LA).